# Clinical Trials
Latest news and articles about Clinical Trials
Total: 6 articles found
China’s Oncology Vanguard: Biotech Innovations Take Center Stage at ASCO 2026
Chinese biotech firms and researchers have achieved a record-breaking presence at the 2026 ASCO Annual Meeting, with 95 abstracts selected for major sessions. Led by STAR Market innovators like BeiGene and Biokin, this surge reflects China's transition from a generic-drug manufacturer to a global leader in high-impact oncology research.
Protecting the Lab: China Solidifies Drug Data Protection in Historic Regulatory Overhaul
China has implemented a major revision to its drug administration laws, introducing a tiered system that protects clinical trial data for up to six years. This reform aims to incentivize high-end pharmaceutical innovation and align China's intellectual property regime with global standards.
The Price of Ambiguity: Why China’s Cardiovascular Giant Salubris is Crashing
Shenzhen Salubris Pharmaceuticals shares hit consecutive limit-down floors after its flagship heart failure drug failed to show statistically significant results in Phase II trials. The sell-off reflects growing investor impatience with China's biotech sector as companies struggle to transition from generics to true innovation.
Turning Back the Biological Clock: Cellular Reprogramming Braces for Human Trials
Partial cellular reprogramming, a biotechnology aimed at reversing the aging process by resetting cellular markers, is set to begin its first human clinical trials this year following promising results in animal models.
Salubris Biotherapeutics Unveils Promising Clinical Data for Novel ADC, Signaling China’s Global Precision Oncology Push
Salubris Biotherapeutics has reported positive Phase 1/2 clinical data for its 5T4-targeting ADC, JK06, at the AACR 2026 conference. The drug shows promising safety and efficacy in treating advanced lung and breast cancers, marking a key advancement in the company's international clinical pipeline.
The Great Leap for Regenerative Medicine: Japan’s Regulatory Gamble Sparks a Global iPSC Race
The global iPSC therapy market has entered a critical clinical phase following Japan's landmark 2026 conditional approvals for heart failure and Parkinson's treatments. While breakthroughs in China and the US demonstrate the curative potential for chronic diseases, the industry must now solve the dual challenges of high manufacturing costs and regulatory safety monitoring.